Kymera Therapeutics Inc (KYMR) News

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the...

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the...

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models...

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven...

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]